Ipsen获得了中国开发的抗体抗癌药物的权利,用于临床发展。 Ipsen acquires rights to a Chinese-developed cancer antibody drug for clinical development.

Ipsen通过获得中国一家生物技术公司Simcere Zaiming创新型抗体药物联合体的权利,扩大了其早期发展管道。 Ipsen has expanded its early-stage development pipeline by acquiring rights to an innovative antibody drug conjugate from Simcere Zaiming, a Chinese biotech company. 该药物旨在精确地针对特定癌症细胞,它标志了Ipsen最近加强其肿瘤学组合的举动。 The drug, designed to target specific cancer cells with precision, marks Ipsen’s latest move to strengthen its oncology portfolio. 该伙伴关系使Ipsen能够将实验疗法推进临床发展,有可能为难以治疗的癌症患者提供新的治疗选择。 The partnership allows Ipsen to advance the experimental therapy into clinical development, potentially offering new treatment options for patients with hard-to-treat cancers.